Ozmosi | Dydrogesterone Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Dydrogesterone

Alternative Names: dydrogesterone, gynorest
Clinical Status: Inactive
Latest Update: 2025-12-18
Latest Update Note: Clinical Trial Update

Product Description

Dydrogesterone is an orally active progestogen which acts directly on the uterus, producing a complete secretory endometrium in an estrogen-primed uterus. At therapeutic levels, dydrogesterone has no contraceptive effect as it does not inhibit or interfere with ovulation or the corpus luteum. Furthermore, dydrogesterone is non-androgenic, non-estrogenic, non-corticoid, non-anabolic and is not excreted as pregnanediol. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Dydrogesterone#section=Pharmacology-and-Biochemistry)

Mechanisms of Action: PR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Countries: Algeria | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Abbott Laboratories
Company Location: Eastern America
Company CEO: Robert B. Ford
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Gynatresia|Menopause|Leiomyoma|Myofibroma|Abortion, Spontaneous|Pregnancy Outcomes|Obstetric Labor, Premature|Fetal Death|Abortion, Habitual|Genital Diseases, Female|Multiple Sclerosis|Infertility, Female|Infertility, Male|Endometrial Cancer|Embryo Loss|Infertility|Abortion, Threatened

Phase 3: Abortion, Habitual|Menopause|Pregnancy Outcomes|Infertility, Male|Abortion, Spontaneous|Infertility, Female|Abortion, Threatened|Menorrhagia|Pelvic Cancer|Liver Cancer|Bone Cancer|Follicular Cyst|Vitamin A Deficiency|Vaginal Cancer|Hypertension, Renal|Protein Deficiency|Genital Cancer, Female|Male Breast Cancer|Weight Loss|Endometrial Cancer|Stroke|Uterine Cancer|Drug Overdose|Body Weight Changes|Vascular Cancer|Weight Gain|Muscle Cancer|Acute Respiratory Distress Syndrome|Kidney Diseases|Obstetric Labor, Premature|Pregnancy, Ovarian|Infertility|Ovarian Cysts|Pregnancy, Abdominal

Phase 2: Anorexia

Phase 1: Ovarian Cysts|Menopause|Infertility|Pregnancy, Ovarian|Follicular Cyst|Polycystic Ovary Syndrome|Conduct Disorder|Pregnancy Outcomes|Hyperandrogenism|Gynatresia

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT06378268

ProGanOS

N/A

Recruiting

Pregnancy Outcomes|Ovarian Cysts|Follicular Cyst|Pregnancy, Ovarian

2025-12-31

2024-04-27

ChiCTR2500096050

Study on the efficacy of different MHT protocols in intervening with cognitive function in perimenopausal and postmenopausal women based on fNIRS detection

N/A

Not yet recruiting

Dementia

2029-12-01

ChiCTR2500113652

ChiCTR2500113652

N/A

Not yet recruiting

Pregnancy Outcomes

2028-12-31

ChiCTR2500103211

ChiCTR2500103211

N/A

Not yet recruiting

Endometriosis

2028-01-31

ChiCTR2400094539

ChiCTR2400094539

N/A

Not yet recruiting

Infertility

2027-12-31

ChiCTR2500110611

ChiCTR2500110611

N/A

Not yet recruiting

Infertility

2027-10-01

ChiCTR2400091369

ChiCTR2400091369

N/A

Not yet recruiting

Injuries/wounds Unspecified

2027-06-30

NCT05847283

DPOS

N/A

Recruiting

Pregnancy Outcomes|Pregnancy, Ovarian|Abortion, Threatened|Obstetric Labor, Premature|Acute Respiratory Distress Syndrome

2027-05-31

2024-11-09

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

ChiCTR2500098020

ChiCTR2500098020

N/A

Recruiting

Infertility

2027-02-26

ChiCTR2400084571

ChiCTR2400084571

N/A

Not yet recruiting

Infertility

2026-12-31

2024-05-22

Treatments

ChiCTR2400079652

ChiCTR2400079652

N/A

Not yet recruiting

Depressive Disorder

2026-11-30

2024-01-11

Treatments

ACTRN12621000439842p

2006-7041-83/hah

N/A

Not yet recruiting

Leukemia

2026-08-03

NCT06952296

Daisy

N/A

Not yet recruiting

Endometriosis

2026-06-30

2025-08-27

Primary Endpoints|Treatments

ChiCTR2400087131

ChiCTR2400087131

N/A

Not yet recruiting

Pregnancy Outcomes

2026-06-01

2024-07-22

Treatments

ChiCTR2400089666

ChiCTR2400089666

N/A

/Completed

Immune Complex Diseases|Periodontal Pocket|Periodontal Diseases|Inflammation|Tooth Loss|Chronic Periodontitis

2026-04-30

ChiCTR2300074428

ChiCTR2300074428

N/A

Not yet recruiting

Endometrial Hyperplasia

2026-01-19

2023-08-08

Treatments

CTR20252416

CTR20252416

N/A

Completed

Menopause

2025-12-08

2025-12-21

Primary Completion Date|Study Completion Date|Treatments|Trial Status

CTR20252417

CTR20252417

N/A

Completed

Menopause

2025-11-04

2025-11-23

Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status

ChiCTR2300077340

ChiCTR2300077340

N/A

Recruiting

Polycystic Ovary Syndrome

2025-11-01

2024-05-26

Treatments

CTR20252451

CTR20252451

N/A

Completed

Menopause

2025-10-08

2025-10-28

Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status

CTR20252555

CTR20252555

N/A

Completed

Menopause

2025-09-20

2025-11-16

Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status

NCT06546397

PRO2023-3733

P1

Recruiting

Pregnancy Outcomes|Gynatresia

2025-09-30

2025-08-29

Primary Endpoints|Treatments

NCT03859921

UW 18-594

P3

Recruiting

Infertility

2025-12-30

2025-06-13

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

2023-509919-89-00

2023-509919-89-00

P4

Recruiting

Infertility, Female|Infertility, Male

2027-10-01

2025-05-02

Treatments

2024-513998-48-00

CS-10459

P4

Recruiting

Unknown

2026-06-30

2025-05-02

Treatments